With 5,179 participants followed for a median of three and a half years, this was the largest trial to address the effect of opening blocked arteries in nonemergency situations and the first to include today’s powerful drug regimens. https://t.co/OYgjkwRBby
— NYT Health (@NYTHealth) November 17, 2019